These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23844623)

  • 1. Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product development.
    Mitra A; Kesisoglou F
    Mol Pharm; 2013 Nov; 10(11):3970-9. PubMed ID: 23844623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using absorption simulation and gastric pH modulated dog model for formulation development to overcome achlorhydria effect.
    Mitra A; Kesisoglou F; Beauchamp M; Zhu W; Chiti F; Wu Y
    Mol Pharm; 2011 Dec; 8(6):2216-23. PubMed ID: 21981752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
    Pang J; Dalziel G; Dean B; Ware JA; Salphati L
    Mol Pharm; 2013 Nov; 10(11):4024-31. PubMed ID: 23980865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
    Good DJ; Hartley R; Mathias N; Crison J; Tirucherai G; Timmins P; Hussain M; Haddadin R; Koo O; Nikfar F; Fung NK
    Mol Pharm; 2015 Dec; 12(12):4434-44. PubMed ID: 26536519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria.
    Kou D; Dwaraknath S; Fischer Y; Nguyen D; Kim M; Yiu H; Patel P; Ng T; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2017 Oct; 14(10):3577-3587. PubMed ID: 28834434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of pH dependent absorption using in vitro, in silico, and in vivo rat models: Early liability assessment during lead optimization.
    Saxena A; Shah D; Padmanabhan S; Gautam SS; Chowan GS; Mandlekar S; Desikan S
    Eur J Pharm Sci; 2015 Aug; 76():173-80. PubMed ID: 25960252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus,™ simulations to predict absorption.
    Bhattachar SN; Perkins EJ; Tan JS; Burns LJ
    J Pharm Sci; 2011 Nov; 100(11):4756-65. PubMed ID: 21681753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a canine model to enable the preclinical assessment of pH-dependent absorption of test compounds.
    Fancher RM; Zhang H; Sleczka B; Derbin G; Rockar R; Marathe P
    J Pharm Sci; 2011 Jul; 100(7):2979-88. PubMed ID: 21254068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers.
    Adachi M; Hinatsu Y; Kusamori K; Katsumi H; Sakane T; Nakatani M; Wada K; Yamamoto A
    Eur J Pharm Sci; 2015 Aug; 76():225-30. PubMed ID: 25988287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model.
    Zhou R; Moench P; Heran C; Lu X; Mathias N; Faria TN; Wall DA; Hussain MA; Smith RL; Sun D
    Pharm Res; 2005 Feb; 22(2):188-92. PubMed ID: 15783065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the risk of pH-dependent absorption for new molecular entities: a novel in vitro dissolution test, physicochemical analysis, and risk assessment strategy.
    Mathias NR; Xu Y; Patel D; Grass M; Caldwell B; Jager C; Mullin J; Hansen L; Crison J; Saari A; Gesenberg C; Morrison J; Vig B; Raghavan K
    Mol Pharm; 2013 Nov; 10(11):4063-73. PubMed ID: 24032349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
    Heigoldt U; Sommer F; Daniels R; Wagner KG
    Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.
    Kuminek G; Salehi N; Waltz NM; Sperry DC; Greenwood DE; Hate SS; Amidon GE
    Mol Pharm; 2023 Jan; 20(1):147-158. PubMed ID: 36367432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389.
    Badawy SI; Gray DB; Zhao F; Sun D; Schuster AE; Hussain MA
    Pharm Res; 2006 May; 23(5):989-96. PubMed ID: 16715389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy.
    Gesenberg C; Mathias NR; Xu Y; Crison J; Savant I; Saari A; Good DJ; Hemenway JN; Narang AS; Schartman RR; Zheng N; Buzescu A; Patel J
    Pharm Res; 2019 Oct; 36(12):164. PubMed ID: 31637544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations.
    Sugawara M; Kadomura S; He X; Takekuma Y; Kohri N; Miyazaki K
    Eur J Pharm Sci; 2005 Sep; 26(1):1-8. PubMed ID: 15961297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study.
    Li S; Pollock-Dove C; Dong LC; Chen J; Creasey AA; Dai WG
    Mol Pharm; 2012 May; 9(5):1100-8. PubMed ID: 22376012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of artificial stomach-duodenum model for investigation of dosing fluid effect on clinical trial variability.
    Polster CS; Atassi F; Wu SJ; Sperry DC
    Mol Pharm; 2010 Oct; 7(5):1533-8. PubMed ID: 20669969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.